Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

209 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells.
Hah JH, Zhao M, Pickering CR, Frederick MJ, Andrews GA, Jasser SA, Fooshee DR, Milas ZL, Galer C, Sano D, William WN Jr, Kim E, Heymach J, Byers LA, Papadimitrakopoulou V, Myers JN. Hah JH, et al. Among authors: papadimitrakopoulou v. Head Neck. 2014 Nov;36(11):1547-54. doi: 10.1002/hed.23499. Epub 2014 Mar 20. Head Neck. 2014. PMID: 24123531 Free PMC article.
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D, Matsumoto F, Valdecanas DR, Zhao M, Molkentine DP, Takahashi Y, Hanna EY, Papadimitrakopoulou V, Heymach J, Milas L, Myers JN. Sano D, et al. Among authors: papadimitrakopoulou v. Clin Cancer Res. 2011 Apr 1;17(7):1815-27. doi: 10.1158/1078-0432.CCR-10-2120. Epub 2011 Feb 24. Clin Cancer Res. 2011. PMID: 21350000 Free PMC article.
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Byers LA, et al. Among authors: papadimitrakopoulou v. Mol Cancer Ther. 2010 Jun;9(6):1755-63. doi: 10.1158/1535-7163.MCT-09-1047. Epub 2010 Jun 8. Mol Cancer Ther. 2010. PMID: 20530716 Free PMC article.
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.
Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Massarelli E, et al. Among authors: papadimitrakopoulou v. Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29. Ann Oncol. 2015. PMID: 26025965 Free PMC article. Clinical Trial.
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.
Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Haddad RI, et al. Among authors: papadimitrakopoulou v. Ann Oncol. 2019 Mar 1;30(3):471-477. doi: 10.1093/annonc/mdy549. Ann Oncol. 2019. PMID: 30596812 Free PMC article. Clinical Trial.
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG; University of Texas M. D. Anderson Lung Cancer Collaborative Research Group. Pataer A, et al. J Thorac Oncol. 2012 May;7(5):825-32. doi: 10.1097/JTO.0b013e318247504a. J Thorac Oncol. 2012. PMID: 22481232 Free PMC article.
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
Hutcheson KA, Lewin JS, Holsinger FC, Steinhaus G, Lisec A, Barringer DA, Lin HY, Villalobos S, Garden AS, Papadimitrakopoulou V, Kies MS. Hutcheson KA, et al. Among authors: papadimitrakopoulou v. Head Neck. 2014 Apr;36(4):474-80. doi: 10.1002/hed.23330. Epub 2013 Jun 18. Head Neck. 2014. PMID: 23780650 Free PMC article. Clinical Trial.
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract.
Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Papadimitrakopoulou VA, et al. Arch Otolaryngol Head Neck Surg. 1999 Oct;125(10):1083-9. doi: 10.1001/archotol.125.10.1083. Arch Otolaryngol Head Neck Surg. 1999. PMID: 10522499
Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Lin SH, et al. Among authors: papadimitrakopoulou v. J Thorac Oncol. 2020 Feb;15(2):248-257. doi: 10.1016/j.jtho.2019.10.024. Epub 2019 Nov 25. J Thorac Oncol. 2020. PMID: 31778797 Free article. Clinical Trial.
209 results